Why the study?
Drugs used to treat COVID-19, such as azithromycin and hydroxychloroquine, can prolong the QT interval and increase the risk of pirouette tachycardia and sudden cardiac death.
Does drug treatment for COVID-19 (azithromycin and hydroxychloroquine) increase the risk of QT prolongation and sudden cardiac death in patients with COVID-19?
Does drug treatment for COVID-19 (azithromycin and hydroxychloroquine) increase the risk of QT prolongation and sudden cardiac death in patients with COVID-19?
Azithromycin and hydroxychloroquine used for COVID-19 treatment carry a risk of QT prolongation and sudden cardiac death, requiring careful patient management.
Answers are grounded in this paper and cite their sources.
Requires ECG monitoring with QT-prolonging COVID-19 therapies; leaves open optimal risk stratification for prospective trials.
Since the first case recorded in the end of 2019, the virus SARS-CоV-2 and the related lung disease COVID-19 have spread over the world and became a threat for public health. The drugs used for treatment of this disease (azithromycin and hydroxychloroquine) can prolong the QT interval on the electrocardiogram to increase the risk of pirouette tachycardia and sudden cardiac death. This article presents a review of potential risks related with the drug treatment of COVID-19 and provides recommendations for management of patients during the pandemic.
No takes yet. Share an insight, caveat, or question.
Комолятова et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: